Revvity, Inc. (NYSE: RVTY) announces it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to accelerate scientific innovation. ACD/Labs brings deep expertise in supporting analytical and process chemistry within pharmaceutical and chemical R&D workflows.
Read the full article: Revvity to Acquire ACD/Labs to Expand Its Signals Software Capabilities //
Source: https://www.businesswire.com/news/home/20251110692197/en/Revvity-to-Acquire-ACDLabs-to-Expand-its-Signals-Software-Capabilities